Repligen (NASDAQ:RGEN) Upgraded by Zacks Research to Strong-Buy Rating

Zacks Research upgraded shares of Repligen (NASDAQ:RGEN) from a hold rating to a strong-buy rating in a research report report published on Thursday,Zacks.com reports.

Other equities research analysts have also issued reports about the stock. Weiss Ratings upgraded shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, July 14th. Royal Bank Of Canada started coverage on shares of Repligen in a research note on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price objective for the company. JPMorgan Chase & Co. raised their price objective on Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday. HSBC cut their target price on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Finally, Wells Fargo & Company upped their target price on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $166.43.

Repligen Stock Performance

Shares of Repligen stock opened at $141.01 on Thursday. The firm has a market capitalization of $7.95 billion, a P/E ratio of 193.16, a P/E/G ratio of 2.67 and a beta of 1.06. Repligen has a 52 week low of $100.99 and a 52 week high of $175.77. The company has a quick ratio of 7.78, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The firm’s 50 day moving average is $134.66 and its two-hundred day moving average is $131.60.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. During the same quarter in the previous year, the firm earned $0.26 EPS. The company’s revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Research analysts forecast that Repligen will post 2.06 EPS for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Repligen

Several hedge funds have recently made changes to their positions in RGEN. AQR Capital Management LLC acquired a new position in Repligen in the 1st quarter valued at about $262,000. Jones Financial Companies Lllp grew its stake in shares of Repligen by 3,850.6% in the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after purchasing an additional 6,238 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Repligen by 16.8% in the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after purchasing an additional 20,375 shares during the period. Bank of Nova Scotia raised its stake in shares of Repligen by 88.0% during the second quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock worth $3,951,000 after purchasing an additional 14,860 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its holdings in shares of Repligen by 29.7% during the second quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock worth $3,880,000 after purchasing an additional 7,148 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.